Transcription factor myocyte enhancer factor 2D regulates interleukin-10 production in microglia to protect neuronal cells from inflammation-induced death

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Yang, Shaosong ^a   Gao, Li ^a   Lu, Fangfang ^a   Wang, Bao ^a   Gao, Fei ^a   Zhu, Gang ^a   Cai, Zhibiao ^a   Lai, Juan ^a   Yang, Qian ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

IL 10; MEF2D; Microglia; Neuroinflammation; Parkinson's disease

Indexed keywords

INTERLEUKIN 10; LENTIVIRUS VECTOR; LIPOPOLYSACCHARIDE; MESSENGER RNA; MYOCYTE ENHANCER FACTOR 2; MYOCYTE ENHANCER FACTOR 2D; NEUTRALIZING ANTIBODY; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL ACTIVATION; CELL STIMULATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE SILENCING; GLIA CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; INTERLEUKIN 10 GENE; MALE; MICROGLIA; MOUSE; MTT ASSAY; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PARKINSON DISEASE; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STIMULUS RESPONSE; TRANSCRIPTION REGULATION; ANIMAL; APOPTOSIS; BRAIN; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; NEWBORN; PHYSIOLOGY; TIME FACTOR;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BRAIN; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MALE; MEF2 TRANSCRIPTION FACTORS; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MICROGLIA; RNA, MESSENGER; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84924225509     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0258-z     Document Type: Article

References (40)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5:525-35.
2. Borrajo A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL. Microglial TNF-alpha mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia. 2014;62:145-57.
3. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009;137:47-59.
4. Stone DK, Reynolds AD, Mosley RL, Gendelman HE. Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal. 2009;11:2151-66.
5. Rail D, Scholtz C, Swash M. Post-encephalitic Parkinsonism: current experience. J Neurol Neurosurg Psychiatry. 1981;44:670-6.
6. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand. 1999;100:34-41.
7. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation. 2008;5:8.
8. Qin L, Liu Y, Hong JS, Crews FT. NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia. 2013;61:855-68.
9. Chang RC, Hudson P, Wilson B, Haddon L, Hong JS. Influence of neurons on lipopolysaccharide-stimulated production of nitric oxide and tumor necrosis factor-alpha by cultured glia. Brain Res. 2000;853:236-44.
10. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A. 2003;100:6145-50.
11. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387-94.
12. Napoli I, Neumann H. Microglial clearance function in health and disease. Neuroscience. 2009;158:1030-8.
13. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21:331-44.
14. de Waal MR, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-20.
15. Hart PH, Hunt EK, Bonder CS, Watson CJ, Finlay-Jones JJ. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol. 1996;157:3672-80.
16. Jenkins JK, Malyak M, Arend WP. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res. 1994;13:47-54.
17. Liopeta K, Boubali S, Virgilio L, Thyphronitis G, Mavrothalassitis G, Dimitracopoulos G, et al. cAMP regulates IL-10 production by normal human T lymphocytes at multiple levels: a potential role for MEF2. Mol Immunol. 2009;46:345-54.
18. Boubali S, Liopeta K, Virgilio L, Thyphronitis G, Mavrothalassitis G, Dimitracopoulos G, et al. Calcium/calmodulin-dependent protein kinase II regulates IL-10 production by human T lymphocytes: a distinct target in the calcium dependent pathway. Mol Immunol. 2012;52:51-60.
19. Yu YT, Breitbart RE, Smoot LB, Lee Y, Mahdavi V, Nadal-Ginard B. Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors. Genes Dev. 1992;6:1783-98.
20. Yang Q, Mao Z. Dysregulation of autophagy and Parkinson's disease: the MEF2D link. Apoptosis. 2010;15:1410-4.
21. Gao L, She H, Li W, Zeng J, Zhu J, Jones DP, et al. Oxidation of survival factor MEF2D in neuronal death and Parkinson's disease. Antioxid Redox Signal. 2014;20:2936-48.
22. Son JH, Chun HS, Joh TH, Cho S, Conti B, Lee JW. Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos. J Neurosci. 1999;19:10-20.
23. Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, et al. Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science. 2009;323:124-7.
24. Wilker PR, Kohyama M, Sandau MM, Albring JC, Nakagawa O, Schwarz JJ, et al. Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation. Nat Immunol. 2008;9:603-12.
25. Pan F, Ye Z, Cheng L, Liu JO. Myocyte enhancer factor 2 mediates calcium-dependent transcription of the interleukin-2 gene in T lymphocytes: a calcium signaling module that is distinct from but collaborates with the nuclear factor of activated T cells (NFAT). J Biol Chem. 2004;279:14477-80.
26. Wang B, Cai Z, Lu F, Li C, Zhu X, Su L, et al. Destabilization of survival factor MEF2D mRNA by neurotoxin in models of Parkinson's disease. J Neurochem. 2014;130:720-8.
27. She H, Yang Q, Shepherd K, Smith Y, Miller G, Testa C, et al. Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. J Clin Invest. 2011;121:930-40.
28. Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science. 1999;286:785-90.
29. Chan SF, Sances S, Brill LM, Okamoto S, Zaidi R, McKercher SR, et al. ATM-dependent phosphorylation of MEF2D promotes neuronal survival after DNA damage. J Neurosci. 2014;34:4640-53.
30. Yamada T, Yang Y, Huang J, Coppola G, Geschwind DH, Bonni A. Sumoylated MEF2A coordinately eliminates orphan presynaptic sites and promotes maturation of presynaptic boutons. J Neurosci. 2013;33:4726-40.
31. Swanson BJ, Jack HM, Lyons GE. Characterization of myocyte enhancer factor 2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription factor in lymphocytes. Mol Immunol. 1998;35:445-58.
32. Debnath I, Roundy KM, Pioli PD, Weis JJ, Weis JH. Bone marrow-induced Mef2c deficiency delays B-cell development and alters the expression of key B-cell regulatory proteins. Int Immunol. 2013;25:99-115.
33. Wang RM, Zhang QG, Li J, Yang LC, Yang F, Brann DW. The ERK5-MEF2C transcription factor pathway contributes to anti-apoptotic effect of cerebral ischemia preconditioning in the hippocampal CA1 region of rats. Brain Res. 2009;1255:32-41.
34. Wang X, Tang X, Gong X, Albanis E, Friedman SL, Mao Z. Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. Gastroenterology. 2004;127:1174-88.
35. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71-109.
36. He Z, Guo Q, Xiao M, He C, Zou W. Intrathecal lentivirus-mediated transfer of interleukin-10 attenuates chronic constriction injury-induced neuropathic pain through modulation of spinal high-mobility group box 1 in rats. Pain Physician. 2013;16:E615-25.
37. Avni D, Ernst O, Philosoph A, Zor T. Role of CREB in modulation of TNFalpha and IL-10 expression in LPS-stimulated RAW264.7 macrophages. Mol Immunol. 2010;47:1396-403.
38. Chanteux H, Guisset AC, Pilette C, Sibille Y. LPS induces IL-10 production by human alveolar macrophages via MAPKinases- and Sp1-dependent mechanisms. Respir Res. 2007;8:71.
39. Csoka B, Nemeth ZH, Virag L, Gergely P, Leibovich SJ, Pacher P, et al. A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood. 2007;110:2685-95.
40. Yoshidome H, Kato A, Edwards MJ, Lentsch AB. Interleukin-10 suppresses hepatic ischemia/reperfusion injury in mice: implications of a central role for nuclear factor kappaB. Hepatology. 1999;30:203-8.